Pulmonary hypertension historical perspective: Difference between revisions
Jump to navigation
Jump to search
Jose Loyola (talk | contribs) |
Jose Loyola (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}: {{AE}} {{AG}} | {{CMG}}: {{AE}} {{AG}} | ||
==Overview== | ==Overview== | ||
[[Pulmonary hypertension]] was first described by [[Ernst von Romberg]], a German physician, in 1891. | |||
==Historical Perspective== | ==Historical Perspective== | ||
*[[Pulmonary hypertension]] was first described by [[Ernst von Romberg]], a German physician, in 1891. | *[[Pulmonary hypertension]] was first described by [[Ernst von Romberg]], a German physician, in 1891. | ||
*[[Dresdale]] investigated the effects of [[tolzoline]] in a woman with [[pulmonary arterial hypertension]] causing a sudden reduction in pulmonary vascular resistance; | *[[Dresdale]] investigated the effects of [[tolzoline]] in a woman with [[pulmonary arterial hypertension]] causing a sudden reduction in pulmonary vascular resistance; | ||
*In the late 1960s there was an epidemic of [[pulmonary arterial hypertension]] induced by aminorex which sparked interest on the disease | *In the late 1960s there was an epidemic of [[pulmonary arterial hypertension]] induced by aminorex which sparked interest on the disease; | ||
*[[Pulmonary hypertension]] was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland.<ref name="pmid19561874">{{cite journal| author=Barst RJ| title=Pulmonary hypertension: past, present and future. | journal=Ann Thorac Med | year= 2008 | volume= 3 | issue= 1 | pages= 1-4 | pmid=19561874 | doi=10.4103/1817-1737.37832 | pmc=2700428 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19561874 }} </ref> | *[[Pulmonary hypertension]] was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland; | ||
*[[Bosentan]] was approved to treat [[pulmonary hypertension]] in 2001, and [[sildenafil]] was approved in 2005.<ref name="pmid19561874">{{cite journal| author=Barst RJ| title=Pulmonary hypertension: past, present and future. | journal=Ann Thorac Med | year= 2008 | volume= 3 | issue= 1 | pages= 1-4 | pmid=19561874 | doi=10.4103/1817-1737.37832 | pmc=2700428 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19561874 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:46, 25 April 2021
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension historical perspective On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension historical perspective |
|
Risk calculators and risk factors for Pulmonary hypertension historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]: Associate Editor(s)-in-Chief: Anthony Gallo, B.S. [2]
Overview
Pulmonary hypertension was first described by Ernst von Romberg, a German physician, in 1891.
Historical Perspective
- Pulmonary hypertension was first described by Ernst von Romberg, a German physician, in 1891.
- Dresdale investigated the effects of tolzoline in a woman with pulmonary arterial hypertension causing a sudden reduction in pulmonary vascular resistance;
- In the late 1960s there was an epidemic of pulmonary arterial hypertension induced by aminorex which sparked interest on the disease;
- Pulmonary hypertension was first classified into primary and secondary in 1973 during the World Health Organization (WHO) meeting on PH in Geneva, Switzerland;
- Bosentan was approved to treat pulmonary hypertension in 2001, and sildenafil was approved in 2005.[1]
References
- ↑ Barst RJ (2008). "Pulmonary hypertension: past, present and future". Ann Thorac Med. 3 (1): 1–4. doi:10.4103/1817-1737.37832. PMC 2700428. PMID 19561874.